PSUSA/00010488/202505
Submitted by Anonymous (not verified) on 27 January 2026 - 13:10
PSUSA/00010488/202505
Clinical investigation of medicinal products in the treatment of peripheral-arterial occlusive disease - Scientific guideline
Submitted by Anonymous (not verified) on 27 January 2026 - 12:50
Clinical investigation of medicinal products in the treatment of peripheral-arterial occlusive disease - Scientific guideline
Human medicines European public assessment report (EPAR): Leqvio, inclisiran, Date of authorisation: 09/12/2020, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 27 January 2026 - 12:36
Human medicines European public assessment report (EPAR): Leqvio, inclisiran, Date of authorisation: 09/12/2020, Revision: 10, Status: Authorised
Pharmaceutical quality of inhalation and nasal products - Scientific guideline
Submitted by Anonymous (not verified) on 27 January 2026 - 12:15
Pharmaceutical quality of inhalation and nasal products - Scientific guideline
PSUSA/00002303/202505
Submitted by Anonymous (not verified) on 27 January 2026 - 10:54
PSUSA/00002303/202505
PSUSA/00002037/202506
Submitted by Anonymous (not verified) on 27 January 2026 - 10:48
PSUSA/00002037/202506
PSUSA/00001859/202506
Submitted by Anonymous (not verified) on 27 January 2026 - 10:39
PSUSA/00001859/202506
Minutes of the CAT meeting 5-7 November 2025
Submitted by Anonymous (not verified) on 27 January 2026 - 10:32
Minutes of the CAT meeting 5-7 November 2025
Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Date of authorisation: 15/01/2018, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 27 January 2026 - 10:30
Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Date of authorisation: 15/01/2018, Revision: 18, Status: Authorised
PSUSA/00002131/202503
Submitted by Anonymous (not verified) on 27 January 2026 - 10:28
PSUSA/00002131/202503